Skip to main content

Advertisement

Table 1 Meta-analysis of the APOB rs693 polymorphism with plasma APOB and lipid levels

From: Associations of the APOB rs693 and rs17240441 polymorphisms with plasma APOB and lipid levels: a meta-analysis

Groups or subgroups Comparisons (Subjects) P Heterogeneity SMD (95% CI) P SMD
APOB
 All 63 (12,364) < 0.01 0.26 (0.16–0.36) < 0.01
 Studies in HWE 53 (10,818) < 0.01 0.25 (0.14–0.36) < 0.01
 Male 14 (2620) 0.13 0.12 (0.01–0.24) 0.03
 Female 7 (1014) 0.37 0.29 (0.12–0.45) < 0.01
 Caucasian 21 (5512) < 0.01 0.19 (0.08–0.30) < 0.01
 Asian 38 (6129) < 0.01 0.34 (0.16–0.51) < 0.01
 CHD 9 (1198) 0.03 0.17 (−0.05–0.38) 0.12
 Healthy or control 39 (8829) < 0.01 0.25 (0.12–0.38) < 0.01
 Case-control studies 34 (4971) < 0.01 0.15 (0.05–0.25) < 0.01
 Cohort studies 29 (7393) < 0.01 0.41 (0.24–0.57) < 0.01
TG
 All 85 (22,128) < 0.01 0.12 (0.05–0.20) < 0.01
 Studies in HWE 71 (19,590) < 0.01 0.13 (0.05–0.21) < 0.01
 Male 19 (2867) 0.05 0.00 (−0.12–0.11) 0.95
 Female 8 (1077) 0.65 0.10 (−0.05–0.25) 0.19
 Caucasian 26 (5454) 0.14 0.02 (−0.06–0.10) 0.65
 Asian 47 (14,257) < 0.01 0.25 (0.12–0.37) < 0.01
 CHD 14 (1716) < 0.01 0.11 (−0.09–0.30) 0.28
 Healthy or control 50 (17,429) < 0.01 0.09 (0.00–0.18) 0.04
 Case-control studies 49 (6571) < 0.01 0.11 (0.00–0.23) 0.05
 Cohort studies 36 (15,557) < 0.01 0.13 (0.03–0.22) 0.01
TC
 All 98 (41,764) < 0.01 0.24 (0.17–0.30) < 0.01
 Studies in HWE 80 (30,373) < 0.01 0.26 (0.18–0.34) < 0.01
 Male 22 (3594) 0.18 0.14 (0.05–0.22) < 0.01
 Female 12 (1362) < 0.01 0.14 (−0.09–0.37) 0.22
 Caucasian 38 (32,268) < 0.01 0.14 (0.09–0.20) < 0.01
 Asian 48 (7080) < 0.01 0.45 (0.25–0.66) < 0.01
 CHD 17 (2076) 0.34 0.13 (0.03–0.24) 0.01
 Healthy or control 52 (10,745) < 0.01 0.28 (0.14–0.41) < 0.01
 Case-control studies 51 (6734) < 0.01 0.19 (0.10–0.28) < 0.01
 Cohort studies 47 (35,030) < 0.01 0.29 (0.19–0.38) < 0.01
LDL-C
 All 82 (22,286) < 0.01 0.22 (0.14–0.30) < 0.01
 Studies in HWE 67 (19,724) < 0.01 0.25 (0.16–0.34) < 0.01
 Male 18 (2685) 0.83 0.18 (0.10–0.27) < 0.01
 Female 9 (1138) < 0.01 0.05 (−0.23–0.33) 0.72
 Caucasian 26 (5893) 0.04 0.17 (0.08–0.26) < 0.01
 Asian 46 (14,268) < 0.01 0.33 (0.19–0.48) < 0.01
 CHD 13 (1624) 0.03 0.07 (−0.09–0.24) 0.38
 Healthy or control 48 (17,243) < 0.01 0.23 (0.13–0.33) < 0.01
 Case-control studies 42 (5871) < 0.01 0.14 (0.05–0.24) < 0.01
 Cohort studies 40 (16,415) < 0.01 0.31 (0.19–0.44) < 0.01
HDL-C
 All 81 (39,292) < 0.01 −0.06 (−0.11–0.01) 0.01
 Studies in HWE 66 (28,316) < 0.01 −0.04 (−0.10–0.01) 0.12
 Male 19 (2912) 0.03 −0.08 (−0.19–0.03) 0.17
 Female 8 (1079) 0.54 −0.02 (−0.17–0.14) 0.84
 Caucasian 26 (30,367) 0.05 −0.04 (−0.08–0.01) 0.11
 Asian 45 (6748) < 0.01 −0.08 (−0.19–0.02) 0.12
 CHD 13 (1665) 0.02 −0.15 (−0.32–0.01) 0.07
 Healthy or control 46 (9700) < 0.01 −0.03 (−0.11–0.05) 0.49
 Case-control studies 43 (6020) < 0.01 −0.05 (−0.14–0.04) 0.29
 Cohort studies 38 (33,272) < 0.01 −0.06 (−0.11–0.00) 0.04
  1. SMD standardized mean difference, 95% CI 95% confidence interval, HWE Hardy-Weinberg equilibrium, APOB apolipoprotein B, TG triglyceride, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol